Severe peanut allergy may be a 'gut reaction'

March 05, 2020

A new study of 19 people who suffer from peanut allergy found an abundance of allergy-causing immunoglobulin E (IgE) antibodies in the gut, providing valuable insights into the mechanisms of severe allergies to peanuts and other foods, which together affect as much as six percent of the U.S. population. The study, published in Science Immunology and accompanied by a Perspective in Science, examined samples of IgE-producing B cells in gut tissue - very difficult to do - from participants beginning a clinical trial for peanut protein oral immunotherapy. The researchers found that antibody-producing B cells in the gut may switch production from harmless types of peanut-targeting antibody to IgE, through a process known as class switch recombination (CSR). The results suggest that targeted prevention of CSR in the gut may be a promising treatment approach. What's more, by defining and locating more IgE antibody types specific to other allergy-inducing foods, such as shellfish and tree nuts, the authors say, scientists could better track patient responses to treatments for these allergy types.

Reactions to food allergy vary widely, from mild inflammation to life-threatening anaphylaxis, depending on what kind of antibody binds to the food antigen. For example, when IgG binds to peanut proteins it is harmless, but binding by IgE can induce anaphylaxis. Few studies have examined IgE-producing B cells in tissues of patients with food allergy, in part because sampling these tissues is difficult and IgE is very short-lived. Here, exploring routine biopsies from 19 patients before they began peanut protein oral immunotherapy treatment, Ramona Hoh and colleagues sequenced antibody genes from B-lineage plasma cells in the stomach, duodenum and esophagus. They found that IgE-producing plasma cells were abundant in the stomach and duodenum. Many patients shared similar peanut-reactive IgE DNA sequences, suggesting that different individuals' immune systems recognize peanut proteins in a similar manner. Hoh et al. also discovered multiple IgE-encoding sequences were shared by other antibodies in the same gut tissues - suggesting that the plasma cells in the gut environment undergo CSR to produce IgE. In a related Science Perspective, Duane Wesemann and Cathryn Nagler argue that determining which features of the gut environment favor CSR to IgE - and what happens to IgE production in the gut after oral immunotherapy - should be high-priority questions for future studies.

On March 26, 2020, Science will host a Facebook Live event focused on Hoh et al.'s work and on peanut allergy more broadly. Reporters and the public alike are welcome to attend the event (to be hosted on this page: https://www.facebook.com/ScienceMagazine) and to ask questions of the experts.
-end-


American Association for the Advancement of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.